Assessing Chemed (CHE) Valuation After Expanded Buyback And Ongoing Dividend Commitment

Simply Wall St

Sun, February 15, 2026 at 2:12 AM GMT+9 3 min read

In this article:

CHE

+2.00%

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Why Chemed’s latest capital return moves matter

Chemed (CHE) is back on investors’ radar after its Board approved an additional US$300 million for share repurchases and reaffirmed a quarterly cash dividend of US$0.60 per share.

Together, the buyback expansion and continued dividend offer a fresh data point on how management is choosing to return capital and how it views the company’s cash generation and balance sheet flexibility.

See our latest analysis for Chemed.

Chemed’s capital return update comes after a period where short term momentum has picked up, with a 1 day share price return of 2.0% and a year to date share price return of 11.66%. This is despite the 1 year total shareholder return being a 14.13% decline and the 5 year total shareholder return being slightly negative at 1.08%.

If this kind of capital return story has your attention, it might be a good moment to widen your watchlist with our 25 healthcare AI stocks as another way to spot potential opportunities in the sector.

With Chemed trading at US$473.22 and sitting at a 27.07% discount to one intrinsic estimate and 17.39% below the current analyst price target, you have to ask: is this a mispricing, or is the market already factoring in future growth?

Most Popular Narrative: 14.8% Undervalued

Against Chemed’s last close of $473.22, the most followed narrative pegs fair value at $555.50. This frames the latest capital returns within a wider earnings and cash flow story.

The consistently strong cash flow from the Roto-Rooter business, despite near-term volume headwinds, underpins Chemed’s ability to pursue opportunistic acquisitions in hospice and drive further consolidation, enhancing future market share and long-term earnings growth.

Read the complete narrative.

Curious what earnings path and margin profile support that fair value gap? The narrative leans on steady top line expansion, firmer profitability, and a richer future earnings multiple.

Result: Fair Value of $555.50 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story could change quickly if Medicare or Medicaid reimbursement terms tighten further, or if Roto Rooter’s weaker residential demand and higher costs persist longer than expected.

Find out about the key risks to this Chemed narrative.

Build Your Own Chemed Narrative

If you see the numbers differently or just like testing your own view against the data, build a quick thesis that reflects your outlook, then Do it your way.

Story Continues  

A great starting point for your Chemed research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Chemed has sharpened your focus, do not stop here. Broaden your search with curated stock ideas built from fresh data and clear fundamental filters.

Target potential value opportunities by scanning our 53 high quality undervalued stocks to highlight companies combining quality fundamentals with prices that may not fully reflect their profile.

Prioritise resilience first and review 85 resilient stocks with low risk scores to see companies that score well on stability, balance sheet strength, and measured risk factors.

Get ahead of the crowd by checking our screener containing 23 high quality undiscovered gems which focuses on solid businesses that are not yet widely followed.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include CHE.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info